基于转座子的癌基因整合在 Abcb4(Mdr2)-/- 小鼠中再现了原发性硬化性胆管炎对胆管癌的高度易感性。

IF 26.8 1区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY
Pinzhu Huang, Guangyan Wei, Jesse D Kirkpatrick, Yi Lin, Li Tan, Heansika Matta, Imad Nasser, Mingzhe Huang, Li Chen, Mathieu Petitjean, Disha Skelton-Badlani, Wen Gao, Kahini Vaid, Shuangshuang Zhao, Alicia Lugovskoy, Maram Alenzi, Xin Chen, Gregory J Gores, Yury V Popov
{"title":"基于转座子的癌基因整合在 Abcb4(Mdr2)-/- 小鼠中再现了原发性硬化性胆管炎对胆管癌的高度易感性。","authors":"Pinzhu Huang, Guangyan Wei, Jesse D Kirkpatrick, Yi Lin, Li Tan, Heansika Matta, Imad Nasser, Mingzhe Huang, Li Chen, Mathieu Petitjean, Disha Skelton-Badlani, Wen Gao, Kahini Vaid, Shuangshuang Zhao, Alicia Lugovskoy, Maram Alenzi, Xin Chen, Gregory J Gores, Yury V Popov","doi":"10.1016/j.jhep.2024.07.016","DOIUrl":null,"url":null,"abstract":"<p><strong>Background & aims: </strong>Cholangiocarcinoma (CCA) is a dreaded complication of primary sclerosing cholangitis (PSC) that is difficult to diagnose and associated with high mortality. Lack of animal models of CCA recapitulating the hepatic microenvironment of sclerosing cholangitis has hindered the development of novel treatments. Herein, we sought to develop a mouse model of PSC-associated CCA.</p><p><strong>Methods: </strong>Ten-week-old Mdr2<sup>-/-</sup> mice with congenital PSC-like disease, and healthy wild-type littermates were subjected to either modified retrograde biliary instillation or hydrodynamic tail vein injection of a sleeping beauty transposon-transposase plasmid system with activated AKT (myr-AKT) and Yap (YapS127A) proto-oncogenes (SB AKT/YAP1). The role of TGFβ was interrogated via ALK5 inhibitor (SB-525334) administration. Tumor phenotype, burden and desmoplastic reaction were analyzed histologically and via RNA sequencing.</p><p><strong>Results: </strong>While SB AKT/YAP1 plasmids administered via retrograde biliary injection caused tumors in Mdr2<sup>-/-</sup>, only 26.67% (4/15) of these tumors were CCA. Alternatively, hydrodynamic tail vein injection of SB AKT/YAP1 resulted in robust tumorigenesis in all fibrotic Mdr2<sup>-/-</sup> mice with high CCA burden compared to healthy mice. Tumors phenotypically resembled human CCA, expressed multiple CCA (but not hepatocellular carcinoma) markers, and exhibited a profound desmoplastic reaction. RNA sequencing analysis revealed profound transcriptional changes in CCA evolving in a PSC-like context, with specific alterations in multiple immune pathways. Pharmacological TGFβ inhibition led to enhanced immune cell tumor infiltration, reduced tumor burden and suppressed desmoplastic collagen accumulation compared to placebo.</p><p><strong>Conclusion: </strong>We established a new high-fidelity cholangiocarcinoma model in mice, termed SB CCA.Mdr2<sup>-/-</sup>, which recapitulates the increased susceptibility to CCA in the setting of biliary injury and fibrosis observed in PSC. Through transcriptomics and pharmacological studies, we show dysregulation of multiple immune pathways and TGFβ signaling as potential drivers of CCA in a PSC-like microenvironment.</p><p><strong>Impact and implications: </strong>Animal models for primary sclerosing cholangitis (PSC)-related cholangiocarcinoma (PSC-CCA) are lacking. Thus, we have developed and characterized a new mouse model of PSC-CCA, termed SB CCA.Mdr2<sup>-/-</sup>, which features reliable tumor induction on a PSC-like background of biliary injury and fibrosis. Global gene expression alterations were identified and standardized tools, including automated whole slide image analysis methodology for tumor burden and feature analysis, were established to enable systematic research into PSC-CCA biology and formal preclinical drug testing.</p>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":null,"pages":null},"PeriodicalIF":26.8000,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Transposon-based oncogene integration in Abcb4(Mdr2)<sup>-/-</sup> mice recapitulates high susceptibility to cholangiocarcinoma in primary sclerosing cholangitis.\",\"authors\":\"Pinzhu Huang, Guangyan Wei, Jesse D Kirkpatrick, Yi Lin, Li Tan, Heansika Matta, Imad Nasser, Mingzhe Huang, Li Chen, Mathieu Petitjean, Disha Skelton-Badlani, Wen Gao, Kahini Vaid, Shuangshuang Zhao, Alicia Lugovskoy, Maram Alenzi, Xin Chen, Gregory J Gores, Yury V Popov\",\"doi\":\"10.1016/j.jhep.2024.07.016\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background & aims: </strong>Cholangiocarcinoma (CCA) is a dreaded complication of primary sclerosing cholangitis (PSC) that is difficult to diagnose and associated with high mortality. Lack of animal models of CCA recapitulating the hepatic microenvironment of sclerosing cholangitis has hindered the development of novel treatments. Herein, we sought to develop a mouse model of PSC-associated CCA.</p><p><strong>Methods: </strong>Ten-week-old Mdr2<sup>-/-</sup> mice with congenital PSC-like disease, and healthy wild-type littermates were subjected to either modified retrograde biliary instillation or hydrodynamic tail vein injection of a sleeping beauty transposon-transposase plasmid system with activated AKT (myr-AKT) and Yap (YapS127A) proto-oncogenes (SB AKT/YAP1). The role of TGFβ was interrogated via ALK5 inhibitor (SB-525334) administration. Tumor phenotype, burden and desmoplastic reaction were analyzed histologically and via RNA sequencing.</p><p><strong>Results: </strong>While SB AKT/YAP1 plasmids administered via retrograde biliary injection caused tumors in Mdr2<sup>-/-</sup>, only 26.67% (4/15) of these tumors were CCA. Alternatively, hydrodynamic tail vein injection of SB AKT/YAP1 resulted in robust tumorigenesis in all fibrotic Mdr2<sup>-/-</sup> mice with high CCA burden compared to healthy mice. Tumors phenotypically resembled human CCA, expressed multiple CCA (but not hepatocellular carcinoma) markers, and exhibited a profound desmoplastic reaction. RNA sequencing analysis revealed profound transcriptional changes in CCA evolving in a PSC-like context, with specific alterations in multiple immune pathways. Pharmacological TGFβ inhibition led to enhanced immune cell tumor infiltration, reduced tumor burden and suppressed desmoplastic collagen accumulation compared to placebo.</p><p><strong>Conclusion: </strong>We established a new high-fidelity cholangiocarcinoma model in mice, termed SB CCA.Mdr2<sup>-/-</sup>, which recapitulates the increased susceptibility to CCA in the setting of biliary injury and fibrosis observed in PSC. Through transcriptomics and pharmacological studies, we show dysregulation of multiple immune pathways and TGFβ signaling as potential drivers of CCA in a PSC-like microenvironment.</p><p><strong>Impact and implications: </strong>Animal models for primary sclerosing cholangitis (PSC)-related cholangiocarcinoma (PSC-CCA) are lacking. Thus, we have developed and characterized a new mouse model of PSC-CCA, termed SB CCA.Mdr2<sup>-/-</sup>, which features reliable tumor induction on a PSC-like background of biliary injury and fibrosis. Global gene expression alterations were identified and standardized tools, including automated whole slide image analysis methodology for tumor burden and feature analysis, were established to enable systematic research into PSC-CCA biology and formal preclinical drug testing.</p>\",\"PeriodicalId\":15888,\"journal\":{\"name\":\"Journal of Hepatology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":26.8000,\"publicationDate\":\"2024-07-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Hepatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.jhep.2024.07.016\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jhep.2024.07.016","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景和目的:胆管癌(CCA)是原发性硬化性胆管炎(PSC)的一种可怕并发症,诊断困难,死亡率高。由于缺乏重现硬化性胆管炎肝脏微环境的 CCA 动物模型,阻碍了新型疗法的开发。在此,我们试图在小鼠中建立这种与 PSC 相关的 CCA 模型:方法:对10周龄患有先天性PSC样疾病的Mdr2-/-小鼠和健康的野生型同窝鼠进行改良逆行胆道灌注或尾静脉注射含有活化的AKT(myr-AKT)和Yap(YapS127A)原癌基因(SB AKT/YAP1)的睡美人转座子-转座酶质粒系统。通过使用 ALK5 抑制剂(SB-525334),研究了 TGFβ 的作用。通过组织学和 RNA-seq 分析了肿瘤表型、负荷和脱鳞反应:结果:虽然逆行胆道注射 SB AKT/YAP1 质粒会导致 Mdr2-/-肿瘤,但这些肿瘤中只有 26.67% (4/15)是 CCA。另外,与健康小鼠相比,通过尾静脉注射SB AKT/YAP1质粒会导致所有纤维化的Mdr2-/-小鼠产生强大的肿瘤,且CCA负荷较高。肿瘤表型与人类 CCA 相似,表达多种 CCA(但不是肝细胞癌)标记物,并表现出深刻的去瘤细胞反应。RNA-seq分析表明,CCA在类PSC背景下发生了深刻的转录变化,多种免疫通路发生了特异性改变。与安慰剂相比,药理 TGFβ 抑制可增强免疫细胞对肿瘤的浸润、减少肿瘤负荷并抑制脱鳞胶原的积累 结论:我们在小鼠中建立了一种新的高保真胆管癌模型,称为 SB CCA.Mdr2-/-,该模型再现了在 PSC 中观察到的胆道损伤和纤维化情况下 CCA 易感性的增加。通过转录组学和药理学研究,我们发现多种免疫通路和 TGFβ 信号转导失调是 PSC 类微环境中 CCA 的潜在驱动因素:目前缺乏原发性硬化性胆管炎相关胆管癌(PSC-CCA)的动物模型。我们开发并鉴定了一种新的 PSC-CCA 小鼠模型,称为 SB CCA.Mdr2-/-,它的特点是在类似 PSC 的胆道损伤和纤维化背景下诱发可靠的肿瘤。我们确定了全局基因表达的改变,并建立了标准化工具,包括用于肿瘤负荷和特征分析的自动化全切片图像分析方法,以实现对 PSC-CCA 生物学的系统研究和正式的临床前药物测试。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Transposon-based oncogene integration in Abcb4(Mdr2)-/- mice recapitulates high susceptibility to cholangiocarcinoma in primary sclerosing cholangitis.

Background & aims: Cholangiocarcinoma (CCA) is a dreaded complication of primary sclerosing cholangitis (PSC) that is difficult to diagnose and associated with high mortality. Lack of animal models of CCA recapitulating the hepatic microenvironment of sclerosing cholangitis has hindered the development of novel treatments. Herein, we sought to develop a mouse model of PSC-associated CCA.

Methods: Ten-week-old Mdr2-/- mice with congenital PSC-like disease, and healthy wild-type littermates were subjected to either modified retrograde biliary instillation or hydrodynamic tail vein injection of a sleeping beauty transposon-transposase plasmid system with activated AKT (myr-AKT) and Yap (YapS127A) proto-oncogenes (SB AKT/YAP1). The role of TGFβ was interrogated via ALK5 inhibitor (SB-525334) administration. Tumor phenotype, burden and desmoplastic reaction were analyzed histologically and via RNA sequencing.

Results: While SB AKT/YAP1 plasmids administered via retrograde biliary injection caused tumors in Mdr2-/-, only 26.67% (4/15) of these tumors were CCA. Alternatively, hydrodynamic tail vein injection of SB AKT/YAP1 resulted in robust tumorigenesis in all fibrotic Mdr2-/- mice with high CCA burden compared to healthy mice. Tumors phenotypically resembled human CCA, expressed multiple CCA (but not hepatocellular carcinoma) markers, and exhibited a profound desmoplastic reaction. RNA sequencing analysis revealed profound transcriptional changes in CCA evolving in a PSC-like context, with specific alterations in multiple immune pathways. Pharmacological TGFβ inhibition led to enhanced immune cell tumor infiltration, reduced tumor burden and suppressed desmoplastic collagen accumulation compared to placebo.

Conclusion: We established a new high-fidelity cholangiocarcinoma model in mice, termed SB CCA.Mdr2-/-, which recapitulates the increased susceptibility to CCA in the setting of biliary injury and fibrosis observed in PSC. Through transcriptomics and pharmacological studies, we show dysregulation of multiple immune pathways and TGFβ signaling as potential drivers of CCA in a PSC-like microenvironment.

Impact and implications: Animal models for primary sclerosing cholangitis (PSC)-related cholangiocarcinoma (PSC-CCA) are lacking. Thus, we have developed and characterized a new mouse model of PSC-CCA, termed SB CCA.Mdr2-/-, which features reliable tumor induction on a PSC-like background of biliary injury and fibrosis. Global gene expression alterations were identified and standardized tools, including automated whole slide image analysis methodology for tumor burden and feature analysis, were established to enable systematic research into PSC-CCA biology and formal preclinical drug testing.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Hepatology
Journal of Hepatology 医学-胃肠肝病学
CiteScore
46.10
自引率
4.30%
发文量
2325
审稿时长
30 days
期刊介绍: The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信